Every Form 4 that NUO THERAPEUTICS INC NEW (AURX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AURX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AURX filings page.
Nuo Therapeutics, Inc. (AURX) director and 10% owner Scott M. Pittman acquired warrants on October 6, 2026, covering 4,500 shares of common stock and a Prepayment Restated Warrant covering a maximum of 458 shares. Both warrants have an exercise price of $1.50 per share and expire January 23, 2031.
The 4,500-share warrant was issued in connection with the assumption of a portion of an assigned funding commitment. The 458-share warrant represents the maximum shares issuable, if at all, in the event of a Prepayment; it vests, if at all, upon a Prepayment, no later than December 31, 2027.
Nuo Therapeutics, Inc. (AURX) reported that CEO/CFO David Emerson Jorden purchased Common Stock in two open-market transactions. On 2026-08-28, he bought 7,984 shares at a weighted average price of $1.089 per share, from $1.08–$1.10. On 2026-08-27, he purchased 789 shares at $1.07 per share. The filing’s Rule 10b5-1 checkbox is not marked as being under a trading plan.
Nuo Therapeutics, Inc. (AURX) reported that its CEO/CFO, Jorden David Emerson, acquired shares of the company’s common stock in two Form 4-reported transactions. On 2026-08-28, he acquired 7,984 shares at a weighted average price of $1.089 per share, executed in multiple trades between $1.08 and $1.10. On 2026-08-27, he acquired an additional 789 shares at $1.07 per share. These are reported as grant/award or other acquisitions, and post-transaction share holdings are not stated in this filing.
Nuo Therapeutics, Inc. reported that CSO/COO Peter Clausen received a grant of options to purchase 65,000 shares of common stock. The options have an exercise price of $1.01 per share and expire on June 29, 2036.
According to the disclosure, one third of these options become exercisable as of June 30, 2027, with the remaining balance vesting quarterly over the following two years. After this grant, Clausen holds options for 65,000 underlying shares directly, reflecting a compensation-related award rather than an open-market trade.
Nuo Therapeutics CEO/CFO David Emerson Jorden exercised 162,500 stock options at $1.00 on June 30, 2026 through a net exercise that delivered 1,608 common shares after 160,892 shares were withheld at $1.01 for exercise price and taxes. He also received a grant of 125,000 options at $1.01 on June 29, 2026, expiring June 29, 2036, with one third exercisable as of June 30, 2027 and the balance vesting quarterly over the following two years. Following these updates and a 25,381-share correction from a prior report, he directly holds 2,061,227 common shares and 125,000 options.
Nuo Therapeutics director and 10% owner Scott M. Pittman reported a compensation-related option exercise and new option grant. He exercised options for 40,000 shares of common stock at $1.00 per share. In a net share settlement, the issuer withheld 39,604 shares at a closing price of $1.01 to cover the exercise cost, and Pittman received 396 net shares.
After the transactions, he directly owns 5,440,000 shares of common stock. He also received a new grant of options for 30,000 shares with an exercise price of $1.01 per share that fully vest as of June 30, 2027 and expire on June 29, 2036. These actions reflect routine equity compensation and tax withholding rather than open-market trading.
Nuo Therapeutics director C. Eric Winzer reported routine equity compensation transactions. On June 30, he exercised stock options for 40,000 shares of common stock at $1.00 per share. The issuer withheld 39,604 shares at the closing price of $1.01 to cover the exercise cost, leaving him with 396 newly issued shares.
Following these transactions, Winzer directly held 173,050 shares of common stock. He also received a new option grant on June 29 for 30,000 shares of common stock at an exercise price of $1.01 per share, vesting fully by June 30, 2027 and expiring on June 29, 2036.
Nuo Therapeutics director Paul Mintz received a stock option grant that increases his potential equity stake. On June 29, 2026, he was awarded options to purchase 30,000 shares of common stock at an exercise price of $1.01 per share. These options fully vest as of June 30, 2027 and expire on June 29, 2036, leaving him with 30,000 derivative securities following the award.
Nuo Therapeutics, Inc. director and CEO/CFO David Emerson Jorden reported acquiring 13,245 shares of Common Stock in a grant or award transaction at a weighted average price of $1.0952 per share. Following this award, he directly holds 2,085,000 shares. A footnote explains the reported price is a weighted average based on multiple transactions with individual share prices ranging from $1.042 to $1.15.
Nuo Therapeutics, Inc. director and 10% owner Scott M. Pittman reported several warrant-related transactions tied to a loan agreement. He received new Prepayment Restated, Second Restated, and Interim Warrants, each exercisable at $1.50 per share of common stock.
The filing shows cancellation of previously issued Second and Prepayment Warrants in exchange for the new restated warrants on similar terms under an Amended and Restated Loan and Security Agreement dated May 29, 2026. After these moves, he directly holds Interim Warrants for 17,450 underlying shares, with additional restated and prepayment warrants vesting only if specified funding or prepayment events occur.
Nuo Therapeutics, Inc. director and 10% owner Scott M. Pittman reported amended details for derivative awards linked to a loan arrangement. On January 23, 2026, he was granted three warrant instruments, each giving the right to buy Common Stock at an exercise price of $1.50 per share and expiring on January 23, 2031.
An integrated Initial Warrant covers 30,050 underlying shares and is immediately exercisable. A Second Warrant covers 36,750 shares and will vest, if at all, on September 30, 2026 if a Second Funding occurs under a Loan and Security Agreement dated January 21, 2026. A Prepayment Warrant covers up to 7,516 shares, vesting only upon a qualifying prepayment, but no later than December 31, 2028, under the same agreement.
The amendment primarily corrects the naming and description of the integrated Initial and Second Warrants while confirming the maximum share amounts and contingent vesting terms tied to the loan agreement.
Nuo Therapeutics director and 10% owner Scott M. Pittman reported receiving several derivative awards in the form of warrants linked to common stock at an exercise price of $1.5 per share on January 23, 2026. The grants include Commitment Warrants, Origination Initial Warrants, Capital Initial Warrants, Origination Second Warrants, Capital Second Warrants, and Prepayment Warrants, each giving the right to buy Nuo Therapeutics common stock and expiring on January 23, 2031.
Certain Second Warrants will vest, if at all, on September 30, 2026 only if a Second Funding occurs under a Loan and Security Agreement dated January 21, 2026. The Prepayment Warrants will vest, if at all, upon a Prepayment event, but no later than December 31, 2028, and the disclosed amount reflects the maximum number of shares issuable upon such a Prepayment. The company’s Board and non-employee directors approved the loan arrangement and the related warrant and share issuances.
Nuo Therapeutics CEO/CFO and director David Jorden reported an insider stock option exercise. On 01/01/2026, he exercised an option to purchase 125,000 shares of Nuo Therapeutics, Inc. common stock at an exercise price of $0.40 per share using a net exercise method.
The company withheld 25,381 shares, valued at the closing price of $1.97 per share, to cover the exercise cost, and Jorden received 99,619 shares of common stock. Following these transactions, he directly beneficially owned 2,046,374 shares of Nuo Therapeutics common stock, and the reported option position was reduced to zero.
Nuo Therapeutics director reports option exercise and share withholding
A director of Nuo Therapeutics, Inc. reported transactions in the company’s common stock dated 12/17/2025. The director exercised an option to purchase 68,750 shares of common stock at an exercise price of $0.4 per share, receiving 55,000 shares on a net basis. The issuer withheld 13,750 shares of common stock underlying the option to cover the exercise price, using the closing price of $2.00 per share. Following these transactions, the director directly beneficially owned 172,654 shares of Nuo Therapeutics common stock.
Nuo Therapeutics, Inc. director reports stock option exercise. A director of Nuo Therapeutics exercised an option to purchase 50,000 shares of common stock at an exercise price of $0.40 per share through a net exercise on December 9, 2025. The transaction resulted in the director receiving 40,909 shares of common stock, while 9,091 shares underlying the option were withheld to cover the exercise price using a closing market price of $2.20 per share. Following these transactions, the director beneficially owns 108,294 shares of Nuo Therapeutics common stock in direct ownership.
Nuo Therapeutics, Inc. director filed a Form 4 reporting an option exercise and related share withholding. On 12/09/2025, the insider exercised an option to purchase 50,000 shares of common stock at an exercise price of $0.40 per share. As part of a net exercise, the issuer withheld 9,091 shares of common stock at a closing price of $2.20 to cover the exercise cost, and the reporting person received 40,909 shares of common stock. Following these transactions, the insider directly beneficially owned 108,294 shares of Nuo Therapeutics common stock.
Nuo Therapeutics, Inc. reported an insider transaction by CEO/CFO and director David Jorden. On 11/28/2025, he reported a sale of 200,000 shares of common stock at $1.50 per share, leaving him with 1,946,755 shares beneficially owned directly after the trade. The filing notes that the transaction was executed as a private transaction in connection with a personal real estate transaction and that the shares involved are characterized as “restricted” securities under the Securities Act of 1933.